6 results about "Caveolin Proteins" patented technology

The present application relates to the field of biological medicine, in particular to a kind of muscone in the application of viral inhibitor.The viral inhibitor of the present application is used to inhibit the replication of Japanese encephalitis virus and / or porcine epidemic diarrhea virus.The present application finds that muscone has no cytotoxicity, and does not directly inactivate virus, but produces antiviral effect on Japanese encephalitis virus by inhibiting NLRP3 / Caspase-1, Caspase-9 / Caspase-3 / Bax / BCL-2, JNK / ERK / P38 and other signal pathways, and inhibits porcine epidemic diarrhea virus invasion into cells by reducing caveolin level.The antiviral effect is remarkable, the mechanism of action is clear, the selectivity is high, and the safety is better.

The application discloses a kind of short peptides simulating RhoE C end, derivative and its pharmaceutical use in treating ventricular remodeling, belong to biological medicine technical field.The short peptide and derivative contain RhoE C end 200-240 linear function domain, can be combined and activated WWP2, remove HGS self-inhibition, start endosome-lysosome degradation pathway.Short peptide sequence is as SEQ ID NO.1, derivative can be coupled with TAT, T7 or RVG membrane penetrating peptide (SEQ ID NO.2-4), and endocytosed to myocardial cell by caveolin high efficiency delivery.The application solves the defects that existing anti-ventricular remodeling drug inhibits protective autophagy flow, and the ability of eliminating toxic protein is limited, can efficiently eliminate damaged mitochondria and misfolded protein, inhibits myocardial hypertrophy, fibrosis, improves cardiac remodeling, provides safe and effective treatment strategy for related diseases.

This invention discloses a short peptide and its derivatives that mimic the N-terminus of RhoE, and their pharmaceutical applications in the treatment of myocardial hypertrophy, belonging to the field of biomedical technology. This short peptide precisely mimics the amino acid sequence from position 1 to 20 of RhoE, specifically binding to the WW domain of WWP2 and competitively blocking the interaction between the N-Loop and C-Loop of its HECT domain. This causes the WWP2 conformation to change from a self-inhibited "closed" state to an activated "open" state, activating E3 ligase activity. The short peptide retains its binding ability to the cardiomyocyte membrane cavernin CAV3, allowing it to efficiently enter the cardiomyocyte cytoplasm via the cavernin endocytosis pathway, overcoming the deficiency of traditional drugs in clearing intracellular pathogenic proteins. Peptide derivatives constructed by fusing transmembrane peptides such as TAT ​​and T7 further improve intracellular delivery efficiency. Experiments have demonstrated that this short peptide and its derivatives can significantly promote WWP2 self-ubiquitination, enhance cardiomyocyte autophagic flux, clear intracellular pathogenic proteins, and effectively inhibit cardiomyocyte hypertrophy, making it suitable for the preparation of anti-myocardial hypertrophy drugs.

The present disclosure relates to modified peptide fragments of the CAV-1 protein and their use in the treatment of fibrosis. Provided herein are compositions comprising a modified caveolar protein 1 (Cav-1) peptide. Also provided are methods of treating pulmonary infection or acute or chronic lung injury, in particular pulmonary fibrosis, using the modified Cav-1 peptides.

The application discloses a preparation method and application of ZnFe2O4@CMD nanoparticles and a magnetic nanoprobe thereof, and discloses a method for regulating transcytosis of a blood-brain barrier (BBB). The application is verified in a BBB in-vitro model and a BBB regulation in a mouse in-vivo. The method of the application enhances the efficiency of molecules or nanoparticles crossing the BBB to enter brain tissues by regulating caveolin-mediated transcytosis of the BBB, and is expected to improve the difficulty of brain disease treatment drugs in crossing the BBB.

This invention discloses the application of a tumor drug marker, the protein kinase HUNK, in the preparation of drugs for treating tumors and metastatic diseases. These drugs include components for inhibiting HUNK expression and nanomedicines. This invention inhibits cellular endocytosis mediated by caveolin, a major pathway for nanomedicines such as albumin-bound paclitaxel to enter cells. The sirna of this protein and its inhibitors can serve as nanomedicine therapies for cancers with high HUNK gene expression. In experimental applications, tumor cells with high HUNK gene expression are insensitive to albumin-bound paclitaxel, while cells treated with HUNK knockout or its inhibitor are more sensitive. Experiments showed that knockout or inhibition of HUNK promotes albumin endocytosis and its entry into lysosomes for degradation.